PLYMOUTH MEETING, PA — Biotechnology firm INOVIO (NASDAQ: INO) has granted a stock option award to a newly hired employee under its 2022 Inducement Plan, part of the company’s ongoing strategy to attract and retain top talent in the competitive biotech sector.
The Compensation Committee of INOVIO’s Board of Directors approved the award on October 31, 2025. The grant consists of an option to purchase 3,000 shares of common stock at an exercise price of $2.35 per share—the closing price of INOVIO’s stock on the grant date.
The stock option will vest over three years, with one-third of the shares vesting on each anniversary of the grant date, contingent upon continued employment with the company. The award was issued in accordance with Nasdaq Listing Rule 5635(c)(4), which permits equity grants to new employees as an inducement for joining a listed company.
INOVIO, headquartered in Plymouth Meeting, Pennsylvania, develops DNA-based medicines designed to help the body produce its own tools to prevent and treat HPV-related diseases, cancer, and infectious illnesses. The company’s platform technology is focused on creating precise, scalable solutions for a range of global health challenges.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.